The Association of G9a Protein and Outcome of Patients With Endometrial Cancer

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01271764

Enrollment

Registered

2011-01-07

Start date

2011-01-31

Completion date

2012-09-30

Last updated

2012-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Outcome of Endometrial Cancer

Brief summary

Tumor invasion and metastasis are the major causes of cancer-related death. Some studies have found that histone methyltransferases, such as EZH2, specifically affect metastasis in breast, gastric and prostate cancer. The functional roles of other members of the HMT family such as G9a in cancer remain obscure. Therefore, the investigators will investigate whether G9a have a role in recurrence/metastasis of endometrial cancer.

Interventions

OTHERno drug

The role of G9a protein in patients with endometrial cancer

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* all cases with endometrial cancer underwent staging operation

Exclusion criteria

* nil

Design outcomes

Primary

Measure	Time frame	Description
The role of G9a protein in endometrial cancer	overall survial, disease-free survival	We will correlate the G9a protein and outcome of endometrial cancer

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026